Document is current

Article History

Accepted: 24 November 2024

First Online: 7 December 2024

Declarations

:

: None.

: MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. WK Seto received speaker’s fees from AstraZeneca, is an advisory board member and received speaker’s fees from Abbott, received research funding from Alexion Pharmaceuticals, Boehringer Ingelheim, Pfizer and Ribo Life Science, and is an advisory board member, received speaker’s fees and researching funding from Gilead Sciences. LY Mak is an advisory board member of Gilead Sciences. RW Hui has no conflict of interests.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: RWHH was involved in data interpretation and drafting of the manuscript. LYM and WKS were involved in critical revision of the manuscript. MFY was involved in study concept, critical revision of the manuscript, and overall study supervision. All authors have seen and approved the final version of the manuscript.